只使用免费官方源：SEC Forms 3/4/5 结构化内部人申报，以及 FINRA Consolidated NMS 场外卖空成交量。 两类数据均保留来源边界，不转写成买卖建议。
SEC 已完成季度 Forms 3/4/5 结构化历史基线 + EDGAR 当前季度 Form 4 增量；个股卡片仅展示当前自然季度的非衍生证券买卖代码 P/S（公开市场或私下交易），成交金额由股数 × 每股价格计算。
官方数据说明| 2026-07-30 2026-07-31 | ACAD ACADIA PHARMACEUTICALS INC | Thompson Elizabeth H.Z. Officer · EVP, Head of Research & Dev | 卖出（S） | 16,508 | US$26.13 | US$431,354.04 | 19,044 | SEC |
| 2026-07-30 2026-07-31 | ACAD ACADIA PHARMACEUTICALS INC | Thompson Elizabeth H.Z. Officer · EVP, Head of Research & Dev | 卖出（S） | 50 | US$26.17 | US$1,308.50 | 18,994 | SEC |
| 2026-07-29 2026-07-31 | KNSA Kiniksa Pharmaceuticals International, plc | Cole G Bradley Director | 卖出（S） | 3,673 | US$81.43 | US$299,092.39 | 11,672 | SEC |
| 2026-07-29 2026-07-31 | DBVT DBV Technologies S.A. | Mohideen Pharis Officer · Chief Medical Officer | 卖出（S） | 464 | US$2.70 | US$1,252.80 | 144,531 | SEC |
| 2026-07-29 2026-07-30 | ANIP ANI PHARMACEUTICALS INC | CAREY STEPHEN P. Officer · SVP & CFO | 卖出（S） | 2,850 | US$81.36 | US$231,876.00 | 174,693 | SEC |
| 2026-07-28 2026-07-30 | KPTI Karyopharm Therapeutics Inc. | Poulton Stuart Officer · EVP, Chief Development Officer | 卖出（S） | 189 | US$7.10 | US$1,341.90 | 94,632 | SEC |
| 2026-07-24 2026-07-28 | ORIC Oric Pharmaceuticals, Inc. | Heyman Richard A. Director | 卖出（S） | 7,000 | US$12.02 | US$84,140.00 | 38,300 | SEC |
| 2026-07-24 2026-07-28 | ORIC Oric Pharmaceuticals, Inc. | Heyman Richard A. Director | 卖出（S） | 6,100 | US$12.02 | US$73,322.00 | 206,672 | SEC |
| 2026-07-24 2026-07-27 | OLMA Olema Pharmaceuticals, Inc. | Harmon Cyrus Director | 卖出（S） | 12,500 | US$11.71 | US$146,425.00 | 702,770 | SEC |
| 2026-07-23 2026-07-27 | OLMA Olema Pharmaceuticals, Inc. | Harmon Cyrus Director | 卖出（S） | 12,500 | US$11.58 | US$144,737.50 | 715,270 | SEC |
| 2026-07-20 2026-07-22 | NAMS NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika Officer · Chief Accounting Officer | 卖出（S） | 70,200 | US$29.96 | US$210.32万 | 59,153 | SEC |
| 2026-07-20 2026-07-22 | NAMS NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika Officer · Chief Accounting Officer | 卖出（S） | 31,885 | US$31.05 | US$990,029.25 | 27,268 | SEC |
| 2026-07-20 2026-07-22 | NAMS NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika Officer · Chief Accounting Officer | 卖出（S） | 2,915 | US$31.71 | US$92,434.65 | 24,353 | SEC |
| 2026-07-20 2026-07-20 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sibold William John Director,Officer · President and CEO | 卖出（S） | 140 | US$542.75 | US$75,984.43 | 211,689 | SEC |
| 2026-07-20 2026-07-20 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sibold William John Director,Officer · President and CEO | 卖出（S） | 280 | US$555.05 | US$155,414.00 | 209,329 | SEC |
| 2026-07-20 2026-07-20 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sibold William John Director,Officer · President and CEO | 卖出（S） | 110 | US$543.79 | US$59,817.22 | 211,579 | SEC |
| 2026-07-20 2026-07-20 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sibold William John Director,Officer · President and CEO | 卖出（S） | 545 | US$544.71 | US$296,869.13 | 211,034 | SEC |
| 2026-07-20 2026-07-20 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sibold William John Director,Officer · President and CEO | 卖出（S） | 275 | US$545.71 | US$150,070.03 | 210,759 | SEC |
| 2026-07-20 2026-07-20 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sibold William John Director,Officer · President and CEO | 卖出（S） | 269 | US$547.08 | US$147,164.20 | 210,490 | SEC |
| 2026-07-20 2026-07-20 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sibold William John Director,Officer · President and CEO | 卖出（S） | 680 | US$547.70 | US$372,434.64 | 209,810 | SEC |
| 2026-07-20 2026-07-20 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sibold William John Director,Officer · President and CEO | 卖出（S） | 47 | US$548.87 | US$25,796.98 | 209,763 | SEC |
| 2026-07-20 2026-07-20 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sibold William John Director,Officer · President and CEO | 卖出（S） | 153 | US$550.01 | US$84,152.11 | 209,610 | SEC |
| 2026-07-20 2026-07-20 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sibold William John Director,Officer · President and CEO | 卖出（S） | 1 | US$550.72 | US$550.72 | 209,609 | SEC |
| 2026-07-17 2026-07-20 | LYEL Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd TenPercentOwner | 卖出（S） | 10 | US$13.70 | US$137.00 | 2,857,480 | SEC |
| 2026-07-16 2026-07-21 | VOR Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. TenPercentOwner | 卖出（S） | 213 | US$19.75 | US$4,206.75 | 4,501,882 | SEC |
| 2026-07-16 2026-07-21 | VOR Vor Biopharma Inc. | RA Capital Healthcare Fund LP TenPercentOwner | 卖出（S） | 213 | US$19.75 | US$4,206.75 | 4,501,882 | SEC |
| 2026-07-16 2026-07-21 | VOR Vor Biopharma Inc. | Kolchinsky Peter TenPercentOwner | 卖出（S） | 213 | US$19.75 | US$4,206.75 | 4,501,882 | SEC |
| 2026-07-16 2026-07-21 | VOR Vor Biopharma Inc. | Shah Rajeev M. TenPercentOwner | 卖出（S） | 213 | US$19.75 | US$4,206.75 | 4,501,882 | SEC |
| 2026-07-16 2026-07-20 | CBIO CRESCENT BIOPHARMA, INC. | Fairmount Funds Management LLC Director,TenPercentOwner | 买入（P） | 853,450 | US$14.50 | US$1237.5万 | 3,601,316 | SEC |
| 2026-07-16 2026-07-20 | CBIO CRESCENT BIOPHARMA, INC. | Fairmount Healthcare Fund II L.P. Director,TenPercentOwner | 买入（P） | 853,450 | US$14.50 | US$1237.5万 | 3,601,316 | SEC |
| 2026-07-16 2026-07-20 | CBIO CRESCENT BIOPHARMA, INC. | Kiselak Tomas Director,TenPercentOwner | 买入（P） | 853,450 | US$14.50 | US$1237.5万 | 3,601,316 | SEC |
| 2026-07-16 2026-07-20 | CBIO CRESCENT BIOPHARMA, INC. | Harwin Peter Evan Director,TenPercentOwner | 买入（P） | 853,450 | US$14.50 | US$1237.5万 | 3,601,316 | SEC |
| 2026-07-16 2026-07-17 | LYEL Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd TenPercentOwner | 卖出（S） | 10 | US$13.73 | US$137.30 | 2,857,490 | SEC |
| 2026-07-16 2026-07-16 | ADIL ADIAL PHARMACEUTICALS, INC. | Coastlands Capital LP TenPercentOwner | 买入（P） | 1,233 | US$2.75 | US$3,390.75 | 388,308 | SEC |
| 2026-07-16 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 19 | US$1.55 | US$29.45 | 743,057 | SEC |
| 2026-07-16 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 19 | US$1.55 | US$29.45 | 743,057 | SEC |
| 2026-07-16 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 19 | US$1.55 | US$29.45 | 743,057 | SEC |
| 2026-07-16 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 19 | US$1.55 | US$29.45 | 743,057 | SEC |
| 2026-07-16 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 2 | US$1.55 | US$3.10 | 75,019 | SEC |
| 2026-07-16 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 2 | US$1.55 | US$3.10 | 75,019 | SEC |
| 2026-07-16 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 2 | US$1.55 | US$3.10 | 75,019 | SEC |
| 2026-07-16 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 2 | US$1.55 | US$3.10 | 75,019 | SEC |
| 2026-07-15 2026-07-17 | INM InMed Pharmaceuticals Inc. | ADAR1 Capital Management, LLC TenPercentOwner | 买入（P） | 1,000 | US$1.56 | US$1,555.00 | 801,000 | SEC |
| 2026-07-15 2026-07-17 | INM InMed Pharmaceuticals Inc. | Schneeberger Daniel TenPercentOwner | 买入（P） | 1,000 | US$1.56 | US$1,555.00 | 801,000 | SEC |
| 2026-07-15 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 13,761 | US$1.55 | US$21,329.55 | 743,038 | SEC |
| 2026-07-15 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 13,761 | US$1.55 | US$21,329.55 | 743,038 | SEC |
| 2026-07-15 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 13,761 | US$1.55 | US$21,329.55 | 743,038 | SEC |
| 2026-07-15 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 13,761 | US$1.55 | US$21,329.55 | 743,038 | SEC |
| 2026-07-15 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 1,389 | US$1.55 | US$2,152.95 | 75,017 | SEC |
| 2026-07-15 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 1,389 | US$1.55 | US$2,152.95 | 75,017 | SEC |
| 2026-07-15 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 1,389 | US$1.55 | US$2,152.95 | 75,017 | SEC |
| 2026-07-15 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 1,389 | US$1.55 | US$2,152.95 | 75,017 | SEC |
| 2026-07-14 2026-07-16 | ADIL ADIAL PHARMACEUTICALS, INC. | Coastlands Capital LP TenPercentOwner | 买入（P） | 2,000 | US$2.65 | US$5,300.00 | 387,075 | SEC |
| 2026-07-14 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 4,882 | US$1.55 | US$7,567.10 | 729,277 | SEC |
| 2026-07-14 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 4,882 | US$1.55 | US$7,567.10 | 729,277 | SEC |
| 2026-07-14 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 4,882 | US$1.55 | US$7,567.10 | 729,277 | SEC |
| 2026-07-14 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 4,882 | US$1.55 | US$7,567.10 | 729,277 | SEC |
| 2026-07-14 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 493 | US$1.55 | US$764.15 | 73,628 | SEC |
| 2026-07-14 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 493 | US$1.55 | US$764.15 | 73,628 | SEC |
| 2026-07-14 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 493 | US$1.55 | US$764.15 | 73,628 | SEC |
| 2026-07-14 2026-07-16 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 493 | US$1.55 | US$764.15 | 73,628 | SEC |
| 2026-07-14 2026-07-16 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc. TenPercentOwner | 卖出（S） | 15,000 | US$37.54 | US$563,146.50 | 2,665,000 | SEC |
| 2026-07-14 2026-07-16 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc. TenPercentOwner | 卖出（S） | 13,315 | US$37.54 | US$499,886.38 | 40,000 | SEC |
| 2026-07-14 2026-07-15 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 卖出（S） | 82,116 | US$4.48 | US$367,879.68 | 0 | SEC |
| 2026-07-13 2026-07-15 | PHVS Pharvaris N.V. | Modig Berndt Director,Officer · Chief Executive Officer | 卖出（S） | 2,292 | US$34.97 | US$80,154.45 | 132,917 | SEC |
| 2026-07-13 2026-07-15 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 卖出（S） | 1,033 | US$4.67 | US$4,824.11 | 60,238 | SEC |
| 2026-07-13 2026-07-14 | ANIP ANI PHARMACEUTICALS INC | Cook Meredith Officer · SR. VP, GENERAL COUNSEL & SEC. | 卖出（S） | 500 | US$81.84 | US$40,920.00 | 77,390 | SEC |
| 2026-07-10 2026-07-13 | ADIL ADIAL PHARMACEUTICALS, INC. | Coastlands Capital LP TenPercentOwner | 买入（P） | 1,700 | US$2.70 | US$4,590.00 | 385,075 | SEC |
| 2026-07-10 2026-07-13 | RDHL RedHill Biopharma Ltd. | Raday Gilead Officer · Chief Operating Officer | 卖出（S） | 14,130,000 | US$0.00 | US$1,413.00 | 218,780,000 | SEC |
| 2026-07-10 2026-07-13 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina Officer · Chief Legal Officer | 卖出（S） | 15,000 | US$17.61 | US$264,121.50 | 179,090 | SEC |
| 2026-07-10 2026-07-13 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 买入（P） | 731 | US$3.11 | US$2,273.41 | 61,271 | SEC |
| 2026-07-10 2026-07-13 | INDV Indivior Pharmaceuticals, Inc. | Heidbreder Christian Officer · Chief Scientific Officer | 卖出（S） | 18,586 | US$41.14 | US$764,628.04 | 209,337 | SEC |
| 2026-07-09 2026-07-13 | ADIL ADIAL PHARMACEUTICALS, INC. | Coastlands Capital LP TenPercentOwner | 买入（P） | 10,053 | US$2.79 | US$28,047.87 | 383,375 | SEC |
| 2026-07-09 2026-07-13 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina Officer · Chief Legal Officer | 卖出（S） | 15,000 | US$18.32 | US$274,746.00 | 194,090 | SEC |
| 2026-07-09 2026-07-13 | BBIO BridgeBio Pharma, Inc. | Cook Jennifer E. Director | 卖出（S） | 36,167 | US$84.00 | US$303.8万 | 120,805 | SEC |
| 2026-07-09 2026-07-13 | BBIO BridgeBio Pharma, Inc. | Cook Jennifer E. Director | 卖出（S） | 112,422 | US$90.00 | US$1011.8万 | 8,383 | SEC |
| 2026-07-09 2026-07-13 | BBIO BridgeBio Pharma, Inc. | Ellis Andrea Director | 卖出（S） | 17,167 | US$84.00 | US$144.2万 | 22,579 | SEC |
| 2026-07-09 2026-07-13 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 买入（P） | 8,266 | US$3.38 | US$27,939.08 | 60,540 | SEC |
| 2026-07-09 2026-07-10 | URGN UroGen Pharma Ltd. | Schoenberg Mark Officer · Chief Medical Officer | 卖出（S） | 10,000 | US$40.00 | US$400,000.00 | 119,763 | SEC |
| 2026-07-09 2026-07-09 | CZFS CITIZENS FINANCIAL SERVICES INC | Gephart LeeAnn Officer · EXECUTIVE VICE PRESIDENT | 卖出（S） | 15 | US$71.52 | US$1,072.80 | 946 | SEC |
| 2026-07-08 2026-07-09 | SNDX Syndax Pharmaceuticals Inc | Metzger Michael A Director,Officer · Chief Executive Officer | 卖出（S） | 32,375 | US$24.24 | US$784,776.48 | 484,843 | SEC |
| 2026-07-08 2026-07-09 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 卖出（S） | 18,531 | US$3.52 | US$65,229.12 | 52,274 | SEC |
| 2026-07-07 2026-07-09 | IONS IONIS PHARMACEUTICALS INC | Kordasiewicz Holly B. Officer · EVP, Chief Development Officer | 卖出（S） | 362 | US$84.30 | US$30,516.60 | 22,096 | SEC |
| 2026-07-07 2026-07-09 | IONS IONIS PHARMACEUTICALS INC | Diaz Allene M. Director | 卖出（S） | 10,111 | US$85.42 | US$863,637.13 | 3,811 | SEC |
| 2026-07-07 2026-07-09 | IONS IONIS PHARMACEUTICALS INC | BENNETT C FRANK Officer · EVP, Chief Scientific Officer | 卖出（S） | 5,536 | US$83.58 | US$462,693.34 | 75,018 | SEC |
| 2026-07-07 2026-07-09 | IONS IONIS PHARMACEUTICALS INC | BENNETT C FRANK Officer · EVP, Chief Scientific Officer | 卖出（S） | 15,000 | US$85.46 | US$128.19万 | 0 | SEC |
| 2026-07-07 2026-07-09 | IRWD IRONWOOD PHARMACEUTICALS INC | Silver Ronald Officer · PFO & PAO | 卖出（S） | 127,890 | US$4.52 | US$578,062.80 | 313,680 | SEC |
| 2026-07-07 2026-07-09 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 卖出（S） | 10,580 | US$3.33 | US$35,231.40 | 70,805 | SEC |
| 2026-07-07 2026-07-09 | RXRX RECURSION PHARMACEUTICALS, INC. | Borgeson Blake Director | 卖出（S） | 40,000 | US$3.96 | US$158,500.00 | 6,218,287 | SEC |
| 2026-07-07 2026-07-08 | TBPH Theravance Biopharma, Inc. | Samaha Eli TenPercentOwner | 卖出（S） | 5,564 | US$17.17 | US$95,540.56 | 9,167,489 | SEC |
| 2026-07-07 2026-07-07 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc. TenPercentOwner | 卖出（S） | 20,000 | US$38.37 | US$767,456.00 | 2,680,000 | SEC |
| 2026-07-07 2026-07-07 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc. TenPercentOwner | 卖出（S） | 6,685 | US$38.37 | US$256,522.17 | 53,315 | SEC |
| 2026-07-07 2026-07-07 | XERS Xeris Biopharma Holdings, Inc. | Pieper Steven Officer · See Remarks | 卖出（S） | 27,600 | US$8.52 | US$235,276.20 | 1,366,053 | SEC |
| 2026-07-06 2026-07-08 | MIRM Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 3,124 | US$121.67 | US$380,097.08 | 44,057 | SEC |
| 2026-07-06 2026-07-08 | MIRM Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 1,048 | US$122.43 | US$128,306.64 | 43,009 | SEC |
| 2026-07-06 2026-07-08 | MIRM Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 528 | US$123.84 | US$65,387.52 | 42,481 | SEC |
| 2026-07-06 2026-07-08 | MIRM Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 300 | US$124.94 | US$37,482.00 | 42,181 | SEC |
| 2026-07-06 2026-07-08 | ORIC Oric Pharmaceuticals, Inc. | Heyman Richard A. Director | 卖出（S） | 300 | US$12.00 | US$3,600.00 | 212,772 | SEC |
| 2026-07-06 2026-07-08 | MIRM Mirum Pharmaceuticals, Inc. | Peetz Christopher Director,Officer · CHIEF EXECUTIVE OFFICER | 卖出（S） | 12,134 | US$121.65 | US$147.61万 | 202,175 | SEC |
| 2026-07-06 2026-07-08 | MIRM Mirum Pharmaceuticals, Inc. | Peetz Christopher Director,Officer · CHIEF EXECUTIVE OFFICER | 卖出（S） | 4,181 | US$122.34 | US$511,503.54 | 197,994 | SEC |
| 2026-07-06 2026-07-08 | MIRM Mirum Pharmaceuticals, Inc. | Peetz Christopher Director,Officer · CHIEF EXECUTIVE OFFICER | 卖出（S） | 1,975 | US$123.74 | US$244,386.50 | 196,019 | SEC |
| 2026-07-06 2026-07-08 | MIRM Mirum Pharmaceuticals, Inc. | Peetz Christopher Director,Officer · CHIEF EXECUTIVE OFFICER | 卖出（S） | 1,710 | US$124.79 | US$213,390.90 | 194,309 | SEC |
| 2026-07-06 2026-07-08 | TBPH Theravance Biopharma, Inc. | Samaha Eli TenPercentOwner | 卖出（S） | 1,400 | US$17.04 | US$23,856.00 | 9,173,053 | SEC |
| 2026-07-06 2026-07-07 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 卖出（S） | 9,022 | US$3.51 | US$31,667.22 | 81,385 | SEC |
| 2026-07-06 2026-07-07 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc. TenPercentOwner | 卖出（S） | 10,000 | US$38.00 | US$380,000.00 | 2,700,000 | SEC |
| 2026-07-06 2026-07-07 | XERS Xeris Biopharma Holdings, Inc. | Pieper Steven Officer · See Remarks | 卖出（S） | 17,400 | US$8.50 | US$147,900.00 | 1,393,653 | SEC |
| 2026-07-02 2026-07-07 | VRTX VERTEX PHARMACEUTICALS INC / MA | McKechnie Duncan Officer · EVP, Chief Commercial Officer | 卖出（S） | 1,541 | US$519.00 | US$799,779.00 | 11,001 | SEC |
| 2026-07-02 2026-07-07 | VRTX VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania Officer · EVP, Chief Reg. & Quality Off. | 卖出（S） | 1,500 | US$524.99 | US$787,485.00 | 45,321 | SEC |
| 2026-07-02 2026-07-07 | REGN REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F Director | 卖出（S） | 200 | US$650.15 | US$130,030.00 | 17,303 | SEC |
| 2026-07-02 2026-07-07 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 买入（P） | 7,851 | US$3.54 | US$27,792.54 | 90,407 | SEC |
| 2026-07-02 2026-07-07 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc. TenPercentOwner | 卖出（S） | 65,000 | US$37.39 | US$243万 | 2,710,000 | SEC |
| 2026-07-02 2026-07-07 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc. TenPercentOwner | 卖出（S） | 25,000 | US$37.39 | US$934,627.50 | 60,000 | SEC |
| 2026-07-02 2026-07-07 | CRNX Crinetics Pharmaceuticals, Inc. | Vivaldi Coelho Rogerio Director | 卖出（S） | 3,000 | US$40.00 | US$120,000.00 | 19,225 | SEC |
| 2026-07-02 2026-07-06 | ANIP ANI PHARMACEUTICALS INC | CAREY STEPHEN P. Officer · SVP & CFO | 卖出（S） | 3,313 | US$86.00 | US$284,918.00 | 177,543 | SEC |
| 2026-07-02 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 1,460 | US$1.55 | US$2,263.00 | 724,395 | SEC |
| 2026-07-02 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 1,460 | US$1.55 | US$2,263.00 | 724,395 | SEC |
| 2026-07-02 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 1,460 | US$1.55 | US$2,263.00 | 724,395 | SEC |
| 2026-07-02 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 1,460 | US$1.55 | US$2,263.00 | 724,395 | SEC |
| 2026-07-02 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 147 | US$1.55 | US$227.85 | 73,135 | SEC |
| 2026-07-02 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 147 | US$1.55 | US$227.85 | 73,135 | SEC |
| 2026-07-02 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 147 | US$1.55 | US$227.85 | 73,135 | SEC |
| 2026-07-02 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 147 | US$1.55 | US$227.85 | 73,135 | SEC |
| 2026-07-01 2026-07-06 | IONS IONIS PHARMACEUTICALS INC | KLEIN JOSEPH III Director | 卖出（S） | 99 | US$79.45 | US$7,865.55 | 22,433 | SEC |
| 2026-07-01 2026-07-06 | IONS IONIS PHARMACEUTICALS INC | KLEIN JOSEPH III Director | 卖出（S） | 11,419 | US$79.04 | US$902,550.91 | 11,014 | SEC |
| 2026-07-01 2026-07-06 | VRTX VERTEX PHARMACEUTICALS INC / MA | Liu Joy Officer · EVP and Chief Legal Officer | 卖出（S） | 828 | US$502.71 | US$416,243.88 | 19,131 | SEC |
| 2026-07-01 2026-07-06 | RARE Ultragenyx Pharmaceutical Inc. | Horn Howard Officer · Chief Financial Officer | 卖出（S） | 4,698 | US$33.13 | US$155,644.74 | 100,991 | SEC |
| 2026-07-01 2026-07-06 | JAZZ Jazz Pharmaceuticals plc | COZADD BRUCE C Director | 卖出（S） | 6,000 | US$240.47 | US$144.28万 | 366,682 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 396 | US$308.99 | US$122,359.49 | 46,118 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 104 | US$310.20 | US$32,261.04 | 46,014 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 1,119 | US$311.72 | US$348,814.68 | 44,895 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 1,081 | US$312.28 | US$337,572.95 | 43,814 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 700 | US$313.46 | US$219,420.18 | 43,114 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 100 | US$314.58 | US$31,457.88 | 43,014 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 900 | US$315.78 | US$284,199.75 | 42,114 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 600 | US$317.15 | US$190,291.02 | 41,514 | SEC |
| 2026-07-01 2026-07-02 | ORMP ORAMED PHARMACEUTICALS INC. | Gabay Avraham Officer · Chief Financial Officer | 卖出（S） | 73,360 | US$4.51 | US$330,743.56 | 671,785 | SEC |
| 2026-07-01 2026-07-02 | ORMP ORAMED PHARMACEUTICALS INC. | Hexter Joshua Officer · COO & CBO | 卖出（S） | 137,000 | US$4.46 | US$611,431.00 | 1,023,384 | SEC |
| 2026-07-01 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 3,946 | US$1.55 | US$6,116.30 | 722,935 | SEC |
| 2026-07-01 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 3,946 | US$1.55 | US$6,116.30 | 722,935 | SEC |
| 2026-07-01 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 3,946 | US$1.55 | US$6,116.30 | 722,935 | SEC |
| 2026-07-01 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 3,946 | US$1.55 | US$6,116.30 | 722,935 | SEC |
| 2026-07-01 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 398 | US$1.55 | US$616.90 | 72,988 | SEC |
| 2026-07-01 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 398 | US$1.55 | US$616.90 | 72,988 | SEC |
| 2026-07-01 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 398 | US$1.55 | US$616.90 | 72,988 | SEC |
| 2026-07-01 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 398 | US$1.55 | US$616.90 | 72,988 | SEC |
| 2026-07-01 2026-07-02 | AGIO AGIOS PHARMACEUTICALS, INC. | Gheuens Sarah Officer · Chief Medical Officer | 卖出（S） | 4,007 | US$37.56 | US$150,502.92 | 84,645 | SEC |
| 2026-07-01 2026-07-02 | FENC FENNEC PHARMACEUTICALS INC. | Raykov Rosty Other | 卖出（S） | 9,599 | US$10.41 | US$99,925.59 | 138,855 | SEC |
| 2026-07-01 2026-07-02 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 买入（P） | 3,959 | US$3.30 | US$13,064.70 | 82,556 | SEC |
| 2026-07-01 2026-07-02 | XERS Xeris Biopharma Holdings, Inc. | Hecht Beth Officer · See Remarks | 卖出（S） | 16,666 | US$8.03 | US$133,859.65 | 1,161,128 | SEC |
| 2026-07-01 2026-07-02 | RPRX Royalty Pharma plc | Urist Marshall Officer · EVP, Research & Investments | 卖出（S） | 9,099 | US$55.88 | US$508,453.94 | 0 | SEC |
| 2026-07-01 2026-07-02 | MIRM Mirum Pharmaceuticals, Inc. | Howe Jolanda Officer · SVP, GLOBAL CONTROLLER | 卖出（S） | 2,721 | US$120.00 | US$326,520.00 | 3,114 | SEC |
| 2026-07-01 2026-07-02 | XERS Xeris Biopharma Holdings, Inc. | McCulloch Kevin Officer · See Remarks | 卖出（S） | 90,000 | US$8.03 | US$722,511.00 | 1,691,126 | SEC |
| 2026-07-01 2026-07-01 | PCSA Processa Pharmaceuticals, Inc. | Ng George K Director,Officer · Chief Executive Officer | 买入（P） | 3,057 | US$1.93 | US$5,900.01 | 15,492 | SEC |
| 2026-07-01 2026-07-01 | TBPH Theravance Biopharma, Inc. | Samaha Eli TenPercentOwner | 卖出（S） | 37,799 | US$17.00 | US$642,628.36 | 9,174,453 | SEC |
| 2026-06-30 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 545 | US$1.54 | US$839.30 | 718,989 | SEC |
| 2026-06-30 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 545 | US$1.54 | US$839.30 | 718,989 | SEC |
| 2026-06-30 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 545 | US$1.54 | US$839.30 | 718,989 | SEC |
| 2026-06-30 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 545 | US$1.54 | US$839.30 | 718,989 | SEC |
| 2026-06-30 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC TenPercentOwner | 买入（P） | 55 | US$1.54 | US$84.70 | 72,590 | SEC |
| 2026-06-30 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Fund Holdings, L.P. TenPercentOwner | 买入（P） | 55 | US$1.54 | US$84.70 | 72,590 | SEC |
| 2026-06-30 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman, LLC TenPercentOwner | 买入（P） | 55 | US$1.54 | US$84.70 | 72,590 | SEC |
| 2026-06-30 2026-07-02 | INM InMed Pharmaceuticals Inc. | Vivo Opportunity Cayman Fund, L.P. TenPercentOwner | 买入（P） | 55 | US$1.54 | US$84.70 | 72,590 | SEC |
| 2026-06-30 2026-07-02 | RPRX Royalty Pharma plc | Hite Christopher Officer · EVP & Chairman, Partnering | 卖出（S） | 97,446 | US$56.50 | US$550.6万 | 461,953 | SEC |
| 2026-06-30 2026-07-02 | RPRX Royalty Pharma plc | Hite Christopher Officer · EVP & Chairman, Partnering | 卖出（S） | 2,554 | US$57.10 | US$145,841.32 | 459,399 | SEC |
| 2026-06-30 2026-07-02 | RPRX Royalty Pharma plc | Hite Christopher Officer · EVP & Chairman, Partnering | 卖出（S） | 29,400 | US$56.44 | US$165.94万 | 40,600 | SEC |
| 2026-06-30 2026-07-02 | RPRX Royalty Pharma plc | Hite Christopher Officer · EVP & Chairman, Partnering | 卖出（S） | 600 | US$57.09 | US$34,254.00 | 40,000 | SEC |
| 2026-06-30 2026-07-01 | PCSA Processa Pharmaceuticals, Inc. | Young David Director,Officer · Pres. Research & Development | 买入（P） | 2,531 | US$1.93 | US$4,884.83 | 21,729 | SEC |
| 2026-06-30 2026-07-01 | PCSA Processa Pharmaceuticals, Inc. | SKIBSTED RUSSELL Officer · Chief Financial Officer | 买入（P） | 3,277 | US$1.93 | US$6,324.61 | 16,689 | SEC |
| 2026-06-30 2026-07-01 | PCSA Processa Pharmaceuticals, Inc. | Lin Patrick Officer · Chief Business - Strategy Off | 买入（P） | 2,106 | US$1.93 | US$4,064.58 | 13,113 | SEC |
| 2026-06-30 2026-07-01 | PCSA Processa Pharmaceuticals, Inc. | Guy Wendy Officer · Chief Administrative Officer | 买入（P） | 2,436 | US$1.93 | US$4,701.48 | 14,394 | SEC |
| 2026-06-30 2026-07-01 | NVCT Nuvectis Pharma, Inc. | BENTSUR RON Director,Officer,TenPercentOwner · Chairman & CEO | 买入（P） | 12,500 | US$20.00 | US$250,000.00 | 3,688,424 | SEC |
| 2026-06-30 2026-07-01 | NVCT Nuvectis Pharma, Inc. | Mosseri Marlio Charles TenPercentOwner | 买入（P） | 50,000 | US$18.32 | US$916,000.00 | 3,186,576 | SEC |
| 2026-06-30 2026-07-01 | PHVS Pharvaris N.V. | Lesage Anne Officer · Chief Early Development | 卖出（S） | 30,703 | US$35.49 | US$108.96万 | 93,969 | SEC |
| 2026-06-30 2026-07-01 | PHVS Pharvaris N.V. | Lesage Anne Officer · Chief Early Development | 卖出（S） | 27,872 | US$35.48 | US$988,890.20 | 58,750 | SEC |
| 2026-06-30 2026-07-01 | PHVS Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus Director | 卖出（S） | 30,712 | US$35.49 | US$109万 | 315,167 | SEC |
| 2026-06-30 2026-07-01 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 买入（P） | 6,755 | US$3.23 | US$21,818.65 | 78,597 | SEC |
| 2026-06-30 2026-07-01 | XFOR X4 Pharmaceuticals, Inc | KIRSKE DAVID Officer · Chief Financial Officer | 卖出（S） | 8,543 | US$4.26 | US$36,428.21 | 167,750 | SEC |
| 2026-06-30 2026-07-01 | TBPH Theravance Biopharma, Inc. | Samaha Eli TenPercentOwner | 卖出（S） | 25,027 | US$17.13 | US$428,787.59 | 9,212,252 | SEC |
| 2026-06-29 2026-07-01 | ADIL ADIAL PHARMACEUTICALS, INC. | Coastlands Capital LP TenPercentOwner | 买入（P） | 25,000 | US$2.60 | US$65,000.00 | 373,322 | SEC |
| 2026-06-29 2026-07-01 | PHVS Pharvaris N.V. | Lesage Anne Officer · Chief Early Development | 卖出（S） | 2,300 | US$35.12 | US$80,785.66 | 56,450 | SEC |
| 2026-06-29 2026-07-01 | PHVS Pharvaris N.V. | Lesage Anne Officer · Chief Early Development | 卖出（S） | 8,300 | US$35.05 | US$290,907.53 | 58,750 | SEC |
| 2026-06-29 2026-07-01 | PHVS Pharvaris N.V. | Lesage Anne Officer · Chief Early Development | 卖出（S） | 6,997 | US$35.05 | US$245,231.56 | 124,672 | SEC |
| 2026-06-29 2026-07-01 | PHVS Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus Director | 卖出（S） | 6,888 | US$35.05 | US$241,447.13 | 345,879 | SEC |
| 2026-06-29 2026-07-01 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP TenPercentOwner | 买入（P） | 25,836 | US$3.44 | US$88,875.84 | 71,842 | SEC |
| 2026-06-29 2026-07-01 | TBPH Theravance Biopharma, Inc. | Samaha Eli TenPercentOwner | 卖出（S） | 273,871 | US$17.23 | US$472.01万 | 9,237,279 | SEC |
| 2026-06-29 2026-06-30 | ANIP ANI PHARMACEUTICALS INC | CAREY STEPHEN P. Officer · SVP & CFO | 卖出（S） | 2,850 | US$84.12 | US$239,742.00 | 177,543 | SEC |
| 2026-06-29 2026-06-29 | PHVS Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus Director | 卖出（S） | 2,400 | US$35.10 | US$84,240.00 | 352,767 | SEC |
| 2026-06-26 2026-06-30 | IONS IONIS PHARMACEUTICALS INC | Schneider Eugene Officer · EVP, Chf Clinical Develop Ofcr | 卖出（S） | 26,000 | US$81.05 | US$210.73万 | 77,114 | SEC |
| 2026-06-26 2026-06-30 | IONS IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. Officer · EVP CLO & General Counsel | 卖出（S） | 3,069 | US$80.00 | US$245,520.00 | 61,470 | SEC |
| 2026-06-26 2026-06-30 | IONS IONIS PHARMACEUTICALS INC | Baroldi Joseph Officer · EVP, Chief Business Officer | 卖出（S） | 5,635 | US$80.16 | US$451,701.60 | 4,669 | SEC |
| 2026-06-26 2026-06-30 | VRTX VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen Officer · EVP and CMO | 卖出（S） | 596 | US$482.50 | US$287,570.00 | 15,337 | SEC |
| 2026-06-26 2026-06-29 | PHVS Pharvaris N.V. | Lu Peng Officer · Chief Medical Officer | 卖出（S） | 14,700 | US$34.00 | US$499,800.00 | 65,631 | SEC |
| 2026-06-26 2026-06-29 | PHIO Phio Pharmaceuticals Corp. | Bitterman Robert J Director,Officer · Chairman, Pres. & CEO | 买入（P） | 10,000 | US$0.99 | US$9,900.00 | 421,421 | SEC |
| 2026-06-26 2026-06-29 | ACAD ACADIA PHARMACEUTICALS INC | Kihara James Officer · PRINCIPAL ACCOUNTING OFFICER | 卖出（S） | 11,421 | US$26.08 | US$297,859.68 | 13,088 | SEC |
| 2026-06-26 2026-06-26 | IONS IONIS PHARMACEUTICALS INC | Monia Brett P Director,Officer · Chief Executive Officer | 卖出（S） | 50,000 | US$80.59 | US$402.95万 | 245,571 | SEC |
| 2026-06-25 2026-06-29 | PHVS Pharvaris N.V. | Lu Peng Officer · Chief Medical Officer | 卖出（S） | 3,400 | US$35.09 | US$119,306.00 | 65,631 | SEC |
| 2026-06-25 2026-06-29 | PHVS Pharvaris N.V. | Lu Peng Officer · Chief Medical Officer | 卖出（S） | 11,600 | US$34.45 | US$399,620.00 | 69,031 | SEC |
| 2026-06-25 2026-06-29 | PHVS Pharvaris N.V. | Lesage Anne Officer · Chief Early Development | 卖出（S） | 2,300 | US$35.12 | US$80,776.00 | 56,450 | SEC |
| 代码 | 卖空成交量 | 豁免卖空量 | 场外总成交量 | 卖空量占比 | 报告设施 |
|---|---|---|---|---|---|
| PHAR | 1,875.6058 | 208 | 13,326.5063 | 14.07% | B, Q, N |